Other Clinical Trial - Expanded Access to Veliparib

Status No longer available

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.

Clinical Trial Description

Expanded Access ;

Study Design

Related Conditions & MeSH terms

High Grade Serous Ovarian Cancer
Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Neoplasms

Clinical Trial Details

NCT number	NCT03123211
Study type	Expanded Access
Source	AbbVie
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Withdrawn	`NCT03554109` - QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine	Phase 2
Recruiting	`NCT05088057` - Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer	Phase 2
Recruiting	`NCT05949021` - OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer	Phase 2
Recruiting	`NCT05891171` - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers	Phase 1
Recruiting	`NCT03855358` - A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)	Phase 1
Terminated	`NCT02698176` - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)	Phase 1
Recruiting	`NCT06189209` - Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)	Phase 2
Completed	`NCT02819518` - Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)	Phase 3
Terminated	`NCT03549000` - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.	Phase 1
Completed	`NCT02178722` - Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers	Phase 1/Phase 2
Terminated	`NCT04424641` - A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03742349` - Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).	Phase 1
Recruiting	`NCT03746431` - A Phase 1/2 Study of [225Ac]-FPI-1434 Injection	Phase 1/Phase 2
Recruiting	`NCT05555706` - Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer	Phase 2/Phase 3